COMPARISON OF THE EFFECTS OF INTRALESIONAL TRIAMCINOLONE ACETONIDE TREATMENT WITH INTRALESIONAL VERAPAMIL HYDROCHLORIDE IN PATIENTS PRESENTING WITH SCAR

Main Article Content

Hadia Akram
Rabia Ghafoor
Ramla Moughal
Maria Naseer
Alina Ahmed
Vinesha Devi

Keywords

Intralesional triamcinolone acetonide, intralesional verapamil hydrochloride and scar.

Abstract

Keloid is an abnormal fibrous tissue development extend beyond the incision. Intralesional triamcinolone acetonide is the most used keloids corticosteroid. Intralesional verapamil is new. Both medications were compared to help us choose the best keloids treatment.


OBJECTIVE: To compare the effects of intralesional triamcinolone acetonide treatment with intralesional verapamil hydrochloride in patients presenting with scar at Jinnah Hospital, Karachi.


METHODS: This Randomized was held in the Department of Dermatology, JPMC, Karachi for Six months after approval from 03 July, 2021 till 03 January 2022. Data was prospectively collected from patients after taking a verbal consent. 100 patients who met the diagnostic criteria were included. Quantitative and qualitative data was collected, presented and analyzed. Post stratification chi square test was applied taking p-value of ≤0.05 as significant.


RESULTS: A total of 124 patients who met the inclusion and exclusion criteria were included in this study. Mean age and duration of scar in our study was 48.21±6.24 years and 14.54±9.78 months in the intralesional triamcinolone acetonide group. Mean age and duration of scar in our study was 49.48±8.41 years and 14.97±9.56 months in the intralesional triamcinolone acetonide group.


CONCLUSION: Both triamcinolone and verapamil intralesional injections can achieve scar flattening in hypertrophic scars and keloids. Intralesional triamcinolone continues to be the gold standard for the first line treatment owing to its rapid and effective response.

Abstract 237 | PDF Downloads 110

References

1. Andrews JP, Marttala J, Macarak E, Rosenbloom J, Uitto J. Keloids: the paradigm of skin fibrosis—pathomechanisms and treatment. Matrix Biol 2016; 51:37–46.
2. Shah VV, Aldahan AS, Mlacker S, Alsaidan M, Samarkandy S, Nouri K. 5-Fluorouracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature. Dermatol Ther 2016; 6:169-83.
3. Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconst Surg 2010; 2:557–68.
4. Lee SS, Yosipovitch G, Chan YH, Goh CL. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. J Am Acad Dermatol. 2004;51(6):1002–06.
5. Garg AM, Shah YM, Garg A. The efficacy of intralesional triamcinolone acetonide (20mg/ml) in the treatment of keloid. Int Surg J. 2018;5(3):868–72.
6. Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol. 2007;25(1):26–32.
7. Shanthi FM, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol. 2008;74(4):343.
8. Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns. 2014;40(4):583–88.
9. Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon. 2007; 5:175–80.
10. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment stratigies. Mol Med. 2011; 17:113-5.
11. Boggio RF, Freitas VM, Cassiola FM, Uryabashi M, MachadoSantelli GM. Effect of a calcium channel blocker (verapamil) on the morphology, cytoskeleton and collagenase activity of human skin fibroblasts. Burns 2011; 37:616–25.
12. Yang JY, Huang CY. The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars. Dermatol Surg 2010; 36:1942–9.
13. Uzair M, Butt G, Khurshid K, Suhail Pal S. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-84.
14. Saki N, Mokhtari R, Nozari F. Comparing the Efficacy of intralesional triamcinolone acetonide with verapamil in treatment of keloids: a randomized controlled trial. Dermatol Pract Concept. 2019 Jan 31;9(1):4-9.
15. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. J Burn Care Res 1995; 16:535–8.
16. Muir IF. On the nature of keloid and hypertrophic scars. Br J Plast Surg. 1990; 43:61–9.
17. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999; 104:1435–58.
18. Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg. 2006; 8:362–8.
19. Sephel GC, Woodward SC. Repair, regeneration, and fibrosis. In: Rubin E, editor. Rubin’s Pathology. Lippincott, Williams & Wilkins; Baltimore: 2001. pp. 84–117.
20. Oluwasanmi JO. Keloids in the African. Clin Plast Surg. 1974; 1:179–95.
21. Moustafa MF, Abdel-Fattah MA, Abdel-Fattah DC. Presumptive evidence of the effect of pregnancy estrogens on keloid growth: case report. Plast Reconstr Surg. 1975; 56:450–3.
22. Deitch EA, et al. Hypertrophic burn scars: analysis of variables. J Trauma. 1983; 23:895–8.
23. Lewis WH, Sun KK. Hypertrophic scar: a genetic hypothesis. Burns. 1990; 16:176–8.
24. Murray CJ, Pinnel SR. Keloids and excessive dermal scarring. In: Cohen IK, Diegelmann RF, Lindblad WJ, editors. Woundhealing, Biochemical and Clinical Aspects. Saunders Elsevier; Philadelphia: 1992. pp. 500–9.
25. Bayat A, et al. Keloid disease: clinical relevance of single versus multiple site scars. Br J Plast Surg. 2005; 58:28–37.
26. Marneros AG, et al. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol. 2004; 122:1126–32.
27. Brown JJ, Ollier WE, Thomson W, Bayat A. Positive association of HLA-DRB1*15 with keloid disease in Caucasians. Int J Immunogenet. 2008; 35:303–7.

Most read articles by the same author(s)